Davis Polk advised the joint book-running managers in connection with the $60 million follow-on offering of 4,898,000 shares of common stock of Versartis, Inc. at $12.25 per share. The common stock is listed on the NASDAQ Global Select Market under the symbol “VSAR.”
Based in Menlo Park, California, Versartis is an endocrine-focused biopharmaceutical company developing VRS-317, a novel, long-acting form of recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD).
The Davis Polk corporate team included partner Bruce K. Dallas and associate Marcus K. Hintze. The tax team included partner Lucy W. Farr and associate Catherine L. Chu. The intellectual property and technology team included associates Michelle Ontiveros Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.